Following a hugely successful year in which Cellomatics scooped the Queen’s Award for Enterprise for International Trade earlier this summer, Cellomatics has again been shortlisted as a finalist in the Best CRO category of the 14th Annual OBN Awards.
The winners will be announced on Thursday 17th November at the OBN Awards at The Royal Lancaster Hotel, London.
The OBN Awards, now in their 14th year, are highly regarded UK awards for the Life Sciences industry and aim to celebrate individuals and companies that have made an outstanding impact in their field. The Awards shine a light on companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical need, outstanding company progression and the delivery of real-life tangible results.
The twelve categories awarded on the night encompass the biotech, medtech and digital health sectors, as well as recognising dealmakers and those who provide critical support to innovators across the industry.
Commenting on the announcement, CEO and founder, Dr Shailendra Singh, said: “We are delighted to have been nominated for the second successive year as, I understand it, the standard of entries was extremely high.”
Shailendra added: “It has been a very successful time for us which has recently seen us move to larger, purpose-built facilities and increase capacity of highly skilled scientists as we manage the demand for our preclinical expertise. The team and I recognise what a great honour it is to be recognised as a finalist in the Best CRO category at this year’s awards.”